Elan white paper debunks drug delivery 'myths'

Marc Dresner, former executive editor of Pharma Market Research Report, write in his Drug Delivery Blog about "drug delivery thinking," a term coined by Peter Kramer of Princeton Technology Consulting to refer to the "drug delivery innovation model." Quoting Kramer, Dresner writes, that drug-delivery thinking "could potentially provide 'an alternative to the consolidation approach to problem-solving' now routinely applied as a band-aid to long-term pharma industry sustainability concerns.

Dresner goes on to say that while those who work inside drug delivery already know how it could potentially re-energize the pharmaceutical industry by propelling it forward "in an increasingly uncertain era," many biopharma industry retain some misconceptions about drug delivery. He refers to a white paper on the subject produced by Elan Drug Technologies. The white paper's abstract begins, "The drug delivery market is often viewed as the poor relation of the pharmaceutical industry," but concludes: "...drug delivery is a vibrant source of technology-based product solutions that pharmaceutical companies would be well advised to consider as a means of bolstering their lagging product portfolios."

The white paper lists Elan's "Five Drug Delivery Industry Myths & Realities," which Dresner reprints on his blog "for those of us who recognize the value and untapped potential of drug delivery innovation at a time when the biopharma industry appears to be in a state of flux and in need of fresh solutions to chronic problems."

- read the Drug Delivery Blog post, which ends with Elan's "Five Myths" paper